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S U M M A R Y
We report the case of a 28-year-old previously healthy male who presented with a 1-week history of
fever, headache, vomiting, and jaundice. Blood cultures were positive for group G streptococci and
transesophageal echocardiography demonstrated vegetations on the aortic valve, leading to a deﬁnitive
diagnosis of infective endocarditis. The combination of fever, splenomegaly, anemia, thrombocytopenia,
hypertriglyceridemia, elevated ferritin level, low natural killer (NK) cell activity, and hemophagocytosis
in bone marrow aspirate conﬁrmed the diagnosis of hemophagocytic syndrome (hemophagocytic
lymphohistiocytosis). Antibiotic treatment and intravenous immunoglobulins were administered and
the patient made a full recovery.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Hemophagocytic lymphohistiocytosis (HLH) is a potentially
fatal syndrome that is caused by a stimulated immune response
and is characterized by nonmalignant generalized histiocyte
proliferation with marked hemophagocytosis. This syndrome is
classiﬁed as primary (genetic) or secondary (acquired), related to
severe infections, malignancies, rheumatologic, and metabolic
diseases. Clinical manifestations include fever, hepatosplenome-
galy, bleeding, skin rash, central nervous system (CNS) abnormali-
ties, jaundice, and laboratory ﬁndings of cytopenia, coagulopathy,
hyperlipidemia, hypoﬁbrinogenemia, hyperferritinemia, transa-
minitis, hyperbilirubinemia, hypoalbuminemia, and hyponatre-
mia. Rapid diagnosis is crucial and early therapy with
immunosuppression and/or chemotherapy can be life-saving.
Because infection-associated HLH is rare, no controlled clinical
trials of therapy have been performed. We report a case of HLH as a
complication of group G streptococcal infective endocarditis (GGS-
IE), treated successfully with antibiotics and intravenous immu-
noglobulins (IVIG).* Corresponding author. Tel.: +972 4 8542541; fax: +972 4 8542343.
E-mail address: n_lavi@rambam.health.gov.il (N. Lavi).
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A 28-year-old previously healthy male presented to the
emergency room (ER) with malaise, fever, headache, vomiting,
and jaundice starting 1 week before admission. During initial
evaluation, the patient was alert and hemodynamically stable,
with fever of 38 8C and O2 saturation of 91% in room air. Physical
examination revealed hepatosplenomegaly, but was otherwise
unremarkable.
The blood count showed mild anemia (125 g/l), a normal
leukocyte count, and thrombocytopenia (37  109/l). Creatinine
was normal and there was mild hypokalemia (3 mmol/l) and
hyponatremia (133 mmol/l). Total bilirubin was 7.96 mg/dl, direct
bilirubin was 6.85 mg/dl, and there was a mild elevation of
transaminases. Arterial blood gas analysis revealed hypoxemia and
respiratory alkalosis. The coagulation proﬁle showed an elevated
international normalized ratio (INR; 1.3). Urinalysis was normal.
Blood cultures were obtained, as well as serological tests for
hepatitis A, B, and C viruses, cytomegalovirus (CMV), and Epstein–
Barr virus (EBV).
A chest X-ray was normal. Abdominal ultrasonography showed
hepatosplenomegaly, measuring 19 cm and 18 cm, respectively.
During his ER stay, serology for CMV IgM antibodies was
positive and the patient was admitted to the internal medicine unit
with a presumed diagnosis of infectious mononucleosis. Severalses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Bone marrow aspirate showing hemophagocytosis—macrophages have swallowed neutrophils and platelets (white arrows).
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and worsening hypoxemia, requiring supplemental oxygen.
Repeated chest X-ray showed bilateral interstitial inﬁltrates.
Blood cultures were positive for streptococci. The patient was
transferred to the intensive care unit and gancyclovir, doxycycline,
vancomycin, and ceftriaxone were started. A hematology consul-
tation suggested the possibility of CMV-associated HLH syndrome.
Bone marrow aspiration was consistent with this diagnosis
(Figure 1). Consequently, the patient received four doses of IVIG
(0.5 g/kg/day).
Group G streptococci were identiﬁed in blood cultures. Blood
cultures were positive in three different blood samples, two drawn
>12 h apart. CMV serology was also positive for IgG antibodies, with
high avidity (58%), ruling out acute CMV infection. Based on these
results, gancyclovir, vancomycin, and ceftriaxone were discontinued.
Penicillin and gentamicin were started. After several days of therapy
his respiratory status improved. The platelet count returned to
normal and bilirubin decreased. Thoracic–abdominal–pelvic com-
puterized tomography (CT) was performed to search for signs of
lymphoproliferative disease and the origin of the bacteremia. Peri-
hilar ground glass inﬁltrates, bilateral mild pleural effusion, mild
pericardial effusion, splenic hypodense lesions, hepatoslenomegaly,
and liver hilar and retroperitoneal lymphadenopathy were demon-
strated. A brain CT was normal. Transesophageal echocardiography
revealed aorticvalve vegetations.Thediagnosis of aorticvalve GGS-IE
was established in accordance with the modiﬁed Duke criteria,1
meeting two major criteria: two positive cultures of blood, samples
drawn >12 h apart, and positive echocardiogram with an oscillating
intracardiac mass on the aortic valve. The patient completed 28 days
of antibiotics. Eight weeks later he reported returning to normal life
activities.
3. Discussion
The reported incidence of HLH is 1.2 cases per million per year,
but this is an underestimate. EBV is the most common cause of
infection-associated HLH. Other well-described pathogens are
CMV, parvovirus, herpes simplex virus, varicella zoster virus,
measles virus, human herpesvirus 8 (HHV-8), and HIV. The primary
and secondary forms of HLH are difﬁcult to distinguish as patients
with familial forms of HLH may develop HLH syndrome after a
documented viral infection.
Natural killer (NK) and T cell dysfunction plays a central role in
the pathogenesis of HLH. In primary HLH, dysregulated NK cells fail
to trigger apoptosis of the expanded effector T cell clones and
antigen-presenting cells. The pathogenesis of secondary HLH is
less clear. Patients with secondary HLH may develop quantitative
and functional deﬁciencies of NK cells during their illness. A
subsequent unregulated immune response may result in failure to
remove antigens, which leads to ongoing stimulation of the
immune effector cells. Clinical manifestations are related to thehyperactivation of cytotoxic T lymphocytes and macrophages, the
proliferation, migration, and inﬁltration of these cells into various
organs, and hypercytokinemia of proinﬂammatory cytokines,
resulting in potentially lethal progressive organ dysfunction. A
delay in diagnosis and multi-organ involvement are associated
with a poor prognosis.
Five of the eight criteria established in the Histiocyte Society
trials are required to make the diagnosis of HLH: fever;
splenomegaly; cytopenias (affecting two or more lineages):
hemoglobin <90 g/l, platelets <100  109/l, neutrophils
<1.0  109/l; fasting triglycerides 265 mg/dl and/or ﬁbrinogen
1.5 g/l; hemophagocytosis in bone marrow, spleen, or lymph
nodes; low or absent NK cell activity; ferritin 500 mg/l; soluble
CD25 2400 U/ml. Helpful ﬁndings include conjugated hyperbi-
lirubinemia, transaminitis, hypoalbuminemia, hyponatremia, high
D-dimers, and CNS pleocytosis.
The treatment goal for patients with acquired HLH is to
suppress the severe hyperinﬂammation responsible for the life-
threatening symptoms. Another aim is to kill pathogen-infected
antigen-presenting cells and remove the stimulus for the ongoing
but ineffective T cell activation. Pathogen-directed therapy is
usually insufﬁcient to control hyperinﬂammation.
EBV-associated HLH is almost universally fatal if untreated. The
poor prognosis of this syndrome suggests that patients should be
treated initially with combination chemotherapy and immunother-
apy, regardless of whether they are thought to have familial HLH.
Not all patients with HLH need to be started on the full protocol.
For patients with reactive HLH associated with pathogens other
than EBV, supportive care and treatment of the underlying
infection is associated with a recovery rate of 60–70%. In these
patients, immunosuppressive treatment may be avoided because
of adverse events including myelosuppression. In this patient
population, corticosteroids and immunoglobulin infusions are
sometimes sufﬁcient to control hyperinﬂammation and reverse
the clinical picture. However, the physician should quickly move to
full therapy if the disease does not respond rapidly. Hot et al.2
illustrated the beneﬁt of IVIG (0.5 g/kg/day for 4 days) in CMV-
associated HLH. They proposed that IVIG-based primary regimens
could be adequate for a patient with HLH associated with viruses
other than EBV.
There are only a few published case reports of secondary HLH
related to endocarditis. One case of bacterial endocarditis caused
by Abiotrophia defectiva, a nutritionally variant Streptococcus, in
association with HLH has been published.3 In this case, the patient
was commenced on methylprednisolone, immunoglobulin, and
granulocyte colony-stimulating factor. The response to treatment
was dramatic.
Beta-hemolytic GGS-IE is very uncommon, accounting for less
than 1% of cases of infective endocarditis, and less than 5% of cases
caused by beta-hemolytic streptococci (BHS).4 Baddour5 reported
31 cases of BHS infective endocarditis (BHS-IE) over a 3-year
M. Naffaa et al. / International Journal of Infectious Diseases 17 (2013) e1237–e1239 e1239period. Among them, GGS-IE was discovered in three patients. In
general, BHS-IE occurred frequently in patients with diabetes
mellitus, the majority of them developed complications, and 50%
required surgical valve replacement. The treatment recommenda-
tion usually includes a combination of penicillin and gentamicin.
GGS-IE tends to run an acute course and involves intact and
damaged as well as prosthetic heart valves, usually in patients with
signiﬁcant co-morbidities, with a high rate of extra-cardiac
complications and the need for surgical treatment.
Our patient was a young, previously healthy person who was
diagnosed with deﬁnite GGS-IE according to the modiﬁed Duke’s
diagnostic criteria.1 The patient was diagnosed with HLH syndrome
secondary to GGS-IE, fulﬁlling six of eight criteria, i.e., fever,
splenomegaly, positive bone marrow aspirate, elevated triglycerides
(521 mg/dl), elevated ferritin (1287 mg/l), and low NK cell activity.
Of note, soluble CD25 (one of the HLH criteria) cannot be evaluated at
our institution. The therapy applied resulted in the patient’s full
recovery with no need for surgery. To the best of our knowledge, this
is the ﬁrst report of HLH as a complication of GGS-IE.Patient consent: The patient described in the manuscript has
given oral and written consent for publication of the case report.
Conﬂict of interest: No conﬂict of interest to declare.
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